Neurotransmitter Unveiled as Major Player in Pain Exacerbated by Sleep Loss
A new study has identified a neurotransmitter that plays a major role in chronic pain associated with sleep loss.
Complete the form below to unlock access to ALL audio articles.
People often experience headaches and body pain after a lack of sleep, but the mechanisms behind this phenomenon are unclear. A new study led by investigators at Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB) and published in Nature Communications reveals that a certain chemical messenger, or neurotransmitter, plays a major role.
Through experiments conducted in mice, the researchers found that the heightened pain sensitivity than can result from chronic sleep disruption (CSD)—or CSD-induced hyperalgesia—involved signaling from a part of a brain known as the thalamic reticular nucleus (TRN).
Analyses of metabolites showed that the level of N-arachidonoyl dopamine (NADA), a type of neurotransmitter called an endocannabinoid, decreased in the TRN as a result of sleep deprivation.
Administering NADA to the TRN reduced CSD-induced hyperalgesia in mice.
This beneficial effect of administered NADA could be countered by blocking the cannabinoid receptor 1, suggesting that both the receptor and NADA play a role in pain sensitivity due to sleep deprivation.
“We provide a mechanism as to how sleep disruption leads to exaggerated pain, suggesting that harnessing the endocannabinoid system might break the vicious cycle between pain and sleep loss,” says co–senior author Shiqian Shen, MD, the clinical director of MGH’s Tele Pain Program.
Reference: Ding W, Yang L, Shi E, et al. The endocannabinoid N-arachidonoyl dopamine is critical for hyperalgesia induced by chronic sleep disruption. Nat Commun. 2023;14(1):6696. doi: 10.1038/s41467-023-42283-6
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.